Clinical Resources
Materials for Providers
Standing Orders for Administering Nirsevimab RSV Preventive Antibody (Beyfortus, by Sanofi) to Infants and High-Risk Young Children
Eligible healthcare professionals may vaccinate all infants and high-risk young children who meet the criteria established by the American Academy of Pediatrics (AAP) in September 2026 (https://doi.org/10.1542/peds.2026-079047), for immunization with a long-acting preventive antibody against RSV (nirsevimab, brand name Beyfortus, by Sanofi), with information provided on current CDC recommendations.
Standing Orders for Administering Respiratory Syncytial Virus Vaccine (RSV) to Adults Age 50 Years and Older
Eligible healthcare professionals may vaccinate adults age 50 years and older who meet the criteria established by the CDC’s Advisory Committee on Immunization Practices. These criteria are consistent with the September 2026 recommendations of the American Academy of Family Physicians (AAFP).
Standing Orders for Administering Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants
Eligible healthcare professionals may vaccinate infants younger than 8 months of age who meet the criteria established by the American Academy of Pediatrics (AAP) in September 2026 (https://doi.org/10.1542/peds.2026-079047), for immunization with a long-acting preventive antibody against RSV (clesrovimab, brand name Enflonsia, by Merck).
Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy
Eligible healthcare professionals may vaccinate all pregnant women who meet any of the criteria on this form. This template is consistent with the recommendations of the American College of Obstetricians and Gynecologists.
CDC · FDA · State
ACIP Recommendations
Current Recommendations
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
MMWR August 28, 2025, 74(32);508–514
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices— United States, 2024
MMWR August 15, 2024 / 73(32);696-702
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
MMWR, October 13, 2023, 72(41);1115-1122
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023
MMWR, August 25, 2023, 72(34); 920–925
Vaccine Information Statements
Immunization Information Statement (IIS) – Respiratory Syncytial Virus (RSV) Preventive Antibody VIS
Updated: September 25, 2023
RSV (Respiratory Syncytial Virus) Vaccine VIS
Updated: January 31, 2025
CDC Recommended Schedules
2025 Child and Adolescent Immunization Schedule
- Page count: 15
- Color
- Size: 8.5 ” x 11″
2025 Adult Immunization Schedule
- Page count: 14
- Color
- Size: 8.5 ” x 11″
FDA Package Inserts & EUAs
RSV: Enflonsia Package Insert
Merck
RSV: Mresvia Package Insert
Moderna
RSV: Beyfortus Package Insert
Sanofi
RSV: Arexvy Package Insert
GSK
RSV: Abrysvo Package Insert
Pfizer
Healthcare Professional Organizations
Vaccine Recommendations
AAFP Fall 2026 Immunization Recommendations
The AAFP has released their fall immunization recommendations, reinforcing a commitment to the health of communities across the country. The AAFP urges all adults, children and families to stay up to date on recommended vaccines to keep themselves and their loved ones healthy.
9/2/2026. AAFP Recommendation Statement.
The AAFP is the largest national association of family physicians and supports evidence-based immunization practices for patients of all ages.
AAP Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement
This policy statement updates recommendations of the American Academy of Pediatrics (AAP) for the use of respiratory syncytial virus (RSV) immunization for the prevention of lower respiratory tract infection (LRTI) caused by RSV in infants and children. The AAP recommends RSV immunization for all infants under 8 months of age born during or entering their first RSV season, unless the infant has documented protection from vaccination of their pregnant parent; and for infants and children 8 through 19 months of age who are at high risk of severe RSV disease and entering their second RSV season. The PDF is linked to the companion article from AAP, published as Recommendations for Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Technical Report.
9/2/2026. Pediatrics (2026), DOI: 10.1542/peds.2026-079047
The American Academy of Pediatrics (AAP) is a leading professional organization that develops evidence-based immunization policy and clinical guidance to protect the health of infants, children, and adolescents. AAP supports pediatric clinicians with education, tools, and advocacy to improve vaccination coverage and safety.
IDSA 2026 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients
To support evidence-based clinical & shared decision-making during the 2026-2027 respiratory tract infection season, IDSA developed updated evidence and guidelines for the use of U.S-licensed vaccine against COVID-19, Influenza, and RSV in adult and pediatric patients who are immunocompromised.
9/2/2026. IDSA Practice Advisory
The Infectious Diseases Society of America (IDSA) develops evidence-based immunization policy and recommendations to prevent infectious diseases across populations. Its recommendations include immunocompromised patients.
ACOG Practice Advisory — Maternal Respiratory Syncytial Virus Vaccination
This Practice Advisory provides guidance for the use of respiratory syncytial virus (RSV) vaccine during pregnancy for the prevention of severe RSV disease in young infants.
9/2/2026. ACOG Practice Advisory
The American College of Obstetricians and Gynecologists (ACOG) develops and promotes clinical guidance for safe and effective vaccination of pregnant and reproductive-age patients.
Adult Immunizations as Part of Cardiovascular Care: 2026 ACC Concise Clinical Guidance
The Journal of the American College of Cardiology published Adult Immunizations as Part of Cardiovascular Care: 2026 ACC Concise Clinical Guidance: A Report of the American College of Cardiology [ACC] Solution Set Oversight Committee. Vaccines are essential tools proven to reduce the risk of serious cardiac events that can result from vaccine-preventable diseases, especially in people with preexisting heart disease.
8/5/2026. Journal of the American College of Cardiology. DOI: 10.1016/j.jacc.2026.07.004
The American College of Cardiology (ACC) is a professional medical society dedicated to improving cardiovascular care through education, research, clinical guidelines, and quality improvement.
Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians
The American College of Physicians (ACP) developed these rapid practice points addressing the efficacy, comparative effectiveness, and harms of respiratory syncytial virus (RSV) vaccines in adults aged 18 years or older who are not pregnant or immunocompromised.
3/6/2026. Annals of Internal Medicine; DOI:10.7326/ANNALS-25-05026
The American College of Physicians (ACP) develops evidence-based adult immunization and provides clinical guidance to help internists incorporate vaccines into routine care of adults.
ACOG Committee Statement — Maternal Immunizations
ACOG released updated guidance on maternal immunizations, underscoring the importance of vaccines in protecting pregnant women and their infants.
2/18/2026. Obstetrics & Gynecology; DOI: 10.1097/AOG.0000000000006230
The American College of Obstetricians and Gynecologists (ACOG) develops and promotes clinical guidance for safe and effective vaccination of pregnant and reproductive-age patients.
Recommended Schedules
2026 American Academy of Family Physicians (AAFP) Birth Through Age 18 Immunization Schedule
- Page count: 15
- Color
- Size: 8.5″ x 11″
2026 American Academy of Family Physicians (AAFP) Adults 19 and Older Immunization Schedule
- Page count: 11
- Color
- Size: 8.5″ x 11″
2026 American Academy of Pediatrics’ (AAP) Recommended Child and Adolescent Immunization Schedule
- Page count: 18
- Color
- Size: 8.5″ x 11″
2026 American College of Obstetricians and Gynecologists (ACOG) Maternal Immunization Schedule
- Page count: 4
- Color
- Size: 8.5″ x 11″
